| ¿µ¹® | adverse effect | ÇÑ±Û | ¿ªÈ¿°ú, À¯ÇØÈ¿°ú |
|---|---|---|---|
| ¼³¸í | ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§ ³ªÅ¸³ª´Â Ä¡·á¸ñÀû¿¡ ºÎÇÕµÇÁö ¾Ê´Â ºÒÄèÇÑ ÀÛ¿ë, Áï ºÎÀÛ¿ëÀ» ¿ªÈ¿°ú·Î Ç¥ÇöÇÏ´Â °æ¿ì°¡ ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼´Â ¿ªÈ¿°ú¶õ ¡°¿¹¹æ, Áø´Ü, Ä¡·áÀÇ ¸ñÀûÀ¸·Î »ç¶÷¿¡°Ô »ó¿ë·®ÀÇ ¾àÀ» »ç¿ëÇÏ¿´À» ¶§ ¹ßÇöÇÏ´Â Àå¾Ö·Î, ÀǵµÇÏÁö ¾ÊÀº Àۿ롱À̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. ¾à¹°¿¡ ÀÇÇÑ Ä¡·á¸¦ ÇÒ ¶§, ƯÈ÷ ÁÖ¸ñÇÏ¿©¾ß ÇÒ ÀϹÝÀûÀÎ ¿ªÈ¿°ú·Î¼ ¾à¹°¾Ë·¹¸£±â, Á¶Ç÷Àå±â Àå¾Ö, °£-ÄáÆÏÀÇ Àå¾Ö, ¹°Áú ´ë»ç Àå¾Ö µîÀÌ ÀÖ´Ù. ÀÌ ¿Ü¿¡ ÀÓ»êºÎ¿¡°Ô Åõ¿©ÇÏ¿© ¹ß»ýÇÑ ±âÇü¹ß»ý, ¸¶¾à, °¢¼ºÁ¦, ±âŸ ÇâÁ¤½ÅÁ¦¿¡ ÀÇÇÑ ÀÇÁ¸¼º Çü¼ºµµ Áß¿äÇÏ´Ù. |
||
| AC | abdominal circumference; abdominal compression; absorption coefficient; abuse case; acetate; acetylc... |
|---|---|
| ACD | absolute cardiac dullness; absolute claudication distance; acid-citrate-dextrose [solution]; actinom... |
| ACT | achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ... |
| CAC | cardiac-accelerator center; cardiac arrest code; circulating anticoagulant |
| LA | lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left... |
| AC | Anticoagulant |
|---|---|
| LAC | Lupus AntiCoagulant |
| OAC | Oral anticoagulant |
| OAT | Oral anticoagulant therapy |
| r-TAP | Recombinant tick anticoagulant peptide |
| anticoagulant | <haematology, pharmacology> Any substance that prevents blood clotting. Those drugs administered for prophylaxis or treatment of thromboembolic disorders are heparin, which inactivates thrombin and several other clotting factors and which must be administered parenterally and the oral anticoagulants (warfarin, dicumarol and congeners) which inhibit the hepatic synthesis of vitamin K dependent clotting factors. Anticoagulant solutions used for the preservation of stored whole blood and blood fractions are acid citrate dextrose (ACD), citrate phosphate dextrose (CPD), citrate phosphate dextrose adenine (cPDA 1) and heparin. Anticoagulants used to prevent clotting of blood specimens for laboratory analysis are heparin and several substances that make calcium ions unavailable to the clotting process, including EDTA (ethylenediaminetetraacetic acid), citrate, oxalate and fluoride. (18 Nov 1997) |
|---|---|
| anticoagulant therapy | The use of anticoagulant drugs to reduce or prevent intravascular or intracardiac clotting. (05 Mar 2000) |
| vascular anticoagulant | <protein> Group of calcium-binding proteins that interact with acidic membrane phospholipids in membranes. They contain 4 or 8 repeats of a 61 amino acid domain that folds into 5 a helices. Also known by several other names (e.g. Lipocortins, endonexins), reflecting the history of their discovery in different contexts. See: lipocortin, endonexin I & II, calpactin, p70 and calelectrin. (18 Nov 1997) |
| lupus anticoagulant | An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus. (27 Sep 1997) |
| abscopal effect | A reaction produced following irradiation but occurring outside the zone of actual radiation absorption. (05 Mar 2000) |
| additive effect | <biochemistry, chemistry> An additive effect is the overall biological effect two chemicals acting together and which is the simple sum of the effects of the chemicals acting independently. Compare: antagonism. (15 Jan 1998) |
| adverse effect | This is an abnormal or harmful effect to an organism caused by exposure to a chemical. It is indicated by some result such as death, a change in food or water consumption, altered body and organ weights, altered enzyme levels, or visible illness. An effect may be classed as adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the organism, or increases the susceptibility of the organism to other chemical or biological stress. A non-adverse effect will usually be reversed when the organism is no longer being exposed to the chemical. (09 Oct 1997) |
| Anrep effect | A small transient positive inotropic effect of abrupt increases of systolic aortic and left ventricular pressures related to recovery from transient subendocardial ischemia (e.g., cold pressor test). (05 Mar 2000) |
| antagonistic effect | This is the consequence of one chemical (or group of chemicals) counteracting the effects of another chemical, the opposing chemicals cancel out each other's effects. (09 Oct 1997) |
| Arias-Stella effect | Focal, unusual, decidual changes in endometrial epithelium, consisting of intraluminal budding, and nuclear enlargement and hyperchromatism with cytoplasmic swelling and vacuolation; may be associated with ectopic or uterine pregnancy. Synonym: Arias-Stella effect, Arias-Stella reaction. (05 Mar 2000) |
| Auger effect | <physics> Transition of an electron in an atom from a discrete electronic level to an ionised continuous level with the same energy. Synonym: autoionisation. (13 Jan 1998) |
| autokinetic effect | In psychology, the apparent drifting about of a small, fixed, spot of light which is being observed in a dark room. (05 Mar 2000) |
| Bernoulli effect | <physics> The decrease in fluid pressure that occurs in converting potential to kinetic energy when motion of the fluid is accelerated, in accordance with Bernoulli's law. Applied in water aspirators, atomisers, and humidifiers in which a gas is accelerated across the end of a narrow, fluid-filled orifice. (05 Mar 2000) |
| Bohr effect | <physiology> Decrease in oxygen affinity of haemoglobin when pH decreases or concentration of carbon dioxide increases. (18 Nov 1997) |
| Bowditch effect | Homeometric autoregulation of cardiac function induced by changing heart rate. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|